Crispr Therapeutics AG (CRSP) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $61.74
• Market Cap: $5.30B
• EPS: $-6.47
• 52-Week High: $78.48
• 52-Week Low: $30.04

Market Sentiment

Crispr Therapeutics AG currently has a Neutral sentiment score of -0.02.

About Crispr Therapeutics AG

Crispr Therapeutics AG (CRSP) is a pioneering gene editing company leveraging its proprietary CRISPR/Cas9 technology to develop breakthrough therapies for serious genetic disorders, such as sickle cell disease and beta-thalassemia. Based in Zug, Switzerland, the company is actively expanding its clinical pipeline and forging strategic collaborations to translate its innovative science into effective treatments. With a robust portfolio and a commitment to improving patient outcomes, Crispr The...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Crispr Therapeutics AG and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CRSP pay dividends?

Crispr Therapeutics AG (CRSP) does not currently pay a regular dividend.

What is CRSP's market cap?

Crispr Therapeutics AG (CRSP) has a market capitalization of $5.30B with a current stock price of $61.74.